A RIDDLE WRAPPED IN A MYSTERY INSIDE AN ENIGMA: NHSN SURVEILLANCE DEFINITIONS...2.0!

MSIPC Fall 2016 Interactive Breakout Session Allison Murad, MPH Michigan Department of Health and Human Services



Disclosures

I have nothing to disclose

Fast-Paced Interactive Session

- General NHSN notes and recommendations
- Overview of 2016 changes and FAQs
- 2016 Case Studies
- Overview of TAP Methodology
- TAP Reporting Examples
- Rebaseline/2017 Changes/NHSN v8.6



GENERAL NHSN GUIDANCE

Reporting Reminders

· Always refer to the protocol!

- For NHSN reporting, surveillance determinations "trump" clinical judgement
 - · Clinical diagnoses are important for treatment of individual patients
 - Surveillance definitions are important in identifying trends within a population
- Concerns should be sent to <u>nhsn@cdc.gov</u> instead of not reporting or facility adjudication

CMS Reporting Program	HAI Event	Reporting Specifications	Reporting Start Date
	CLABSI	Adult, Pediatric, and Neonatal ICUs	January 2011
	CAUTI	Adult and Pediatric ICUs	January 2012
	SSI: COLO	Inpatient COLO Procedures	January 2012
	SSI: HYST	Inpatient HYST Procedures	January 2012
Hospital Inpatient Quality Reporting (IQR) Program	MRSA Bacteremia LabID Event	FacWideIN	January 2013
	C. difficile LabID Event	FacWideIN	January 2013
	Healthcare Personnel Influenza Vaccination	All Inpatient Healthcare Personnel	January 2013
	Medicare Beneficiary Number	All Medicare Patients Reported into NHSN	July 2014
	CLABSI	Adult & Pediatric Medical, Surgical, & Medical/Surgical Wards	January 2015
	CAUTI	Adult & Pediatric Medical, Surgical, & Medical/Surgical Wards	January 2015
Hospital Outpatient Quality Reporting (OQR) Program	Healthcare Personnel Influenza Vaccination	All Outpatient Healthcare Personnel	October 2014

CDC-CMS Communique: October 2015

- This document is a reminder that intentionally reporting incorrect data, or deliberately failing to report data that are required to be reported, may violate applicable Medicare laws and regulations
- Continuing concerns as discussed at APIC 2016:
 - Case adjudication and overruling infection preventionists' determinations
 - Departures from standard diagnostic practices to avoid case reporting
 - Time constraints on NHSN training

CDC Websites

 All CDC websites are changing to secure websites (identified by "s" in "https")

 Make sure you are not blocked from accessing by going to: <u>https://www.cdc.gov/nhsn/index.html</u>

Reminder: Update User Info in NHSN

- Make sure the facility administrator and component primary contacts are up-to-date
- Users with administrative rights can reassign the component primary contact role to another active NHSN user
- Only the current facility administrator can reassign this role to another user

Reporting in a Temporarily Closed Location

- Often occurs when a unit undergoes a renovation or is remodeled
- If the whole unit (patients and staff) are being temporarily moved to a different physical location, you can change the "your code" and "your label" values.
 - · No other changes needed as the location type will remain the same
- If patients will temporarily be housed within existing locations, include their data within the reporting from the physical location in which the patients reside
 - Keep the closed location "active" and report "0" for denominator data and check "report no events"



- Reminder: RIT is not a rolling time period
 - Set by date of event and expires after 14 days
 - Other organisms identified within the RIT are added to previous infection's list of pathogens
 - RITs apply to a single admission and do not extend across patient admissions

NEW IN 2016

Non-Culture Based Testing

Non-culture based microbiologic testing method

- Identification of microorganisms using a method of testing other than a culture
- Quicker turnaround time for early diagnosis and tailoring of antimicrobial therapy
- Examples: PCR, ELISA
- Regardless of test methodology used (culture or non-culture based), a final lab report found in the medical record is eligible to meet NHSN definition with exception of those performed for Active Surveillance Culture/Testing (ASC/AST)

Active Surveillance Culture/Testing (ASC/AST)

 Testing intended to identify presence/carriage of microorganisms for the purpose of instituting or discontinuing isolation precautions (ex. Nasal swab for MRSA)

Gross Anatomical Exam

- Physical examination with or without invasive procedure
 - Example: findings elicited or visualized on physical examination or observed during an operative procedure

Brain Dead/Supported for Organ Donation

- · Events should not be reported as an HAI if:
 - · Patient is declared brain dead

AND

- · Patient is being supported for organ donation purposes
- This does not apply to all patients who are declared brain dead
 Example: patient declared brain dead and for whom treatment is limited to comfort care is still to be included in surveillance

Observed or Suspected Patient Accession Documentation that the patient has been observed or suspected of accessing their vascular access lines must appear in the medical record

- · Patient was observed or suspected of injecting into the line
- Does not include manipulation or contamination (ex. patient disconnects, line falls on floor, etc...)
- If positive blood specimen meeting LCBI criteria accompanied by this documentation occurs within the BSI infection window period it will be considered an <u>LCBI but</u> <u>not CLABSI</u>

IAB Criterion Changes

- Criterion 2b was added
 - Abscess or other evidence of intraabdominal infections on gross anatomic or histopathological exam and limited organisms in the blood
 - Organisms in blood performed for purposes of clinical diagnosis or treatment (not active surveillance culture/testing), must contain at least one of the following organisms: Bacteroides spp., Candida spp., Clostridium spp., Enterococcus spp., Fusobacterium spp., Peptostreptococcus spp., Prevotella spp., Veillonella spp., or Enterobacteriaceae with no other recognized cause

IAB Criterion Changes

- Criterion 3b was clarified
 - If the imaging test evidence of infection is equivocal it is supported by clinical correlation (i.e. physician documentation of antimicrobial treatment for an intraabdominal infection)

VASC Reporting Changes

- If LCBI plus culture at a vascular site have at least one matching organism – report LCBI. Report central line "No".
 - Peripheral IV
 - Arteriovenous fistula
 - Arteriovenous graft
 - Non-accessed central line

No Longer Used in NHSN Surveillance

2015:

- · Gap Days concept to determine criterion met
- · Logical pathogens to determine secondary BSI
- Date of Event = Date of last element
- Candida species or yeast not otherwise specified, mold, dimorphic fungi, or parasites are excluded as organisms in the UTI definition

2016:

- Excluded: reporting LCBIs with the following organisms:
 - Blastomyces, Histoplasma, Coccidioides, Paracoccidioides, Cryptococcus, and Pneumocystitis (mainly community-associated and rarely cause HAIs)
 - · Salmonella sp. (highly unlikely to cause primary BSI)
 - May be a secondary BSI but will not be reported as a primary BSI (Especially a CLABSI)

CLABSI AND SECONDARY BSI

Secondary BSI Review

- In order for a bloodstream infection to be determined to be secondary to a primary infection site, the patient must meet all three below:
 - Meet one of the NHSN site-specific definitions for a primary site of infection
 - Have a positive blood culture within the Secondary BSI Attribution Period (infection window period + repeat infection timeframe) or 17 day SSI secondary BSI attribution period
 - Meet requirements in Secondary BSI Scenario 1 or 2

Secondary BSI Scenarios

- Scenario 1: Blood and site-specific specimen cultures match for at least one organism
- Scenario 2: Blood and site-specific specimen cultures do not match
 - If the blood isolate is an element used to meet the site-specific criterion, then the BSI is considered secondary to that site-specific infection
 - If the site-specific culture is an element used to meet the infection site criterion and the blood isolate is not, then the BSI is considered a primary infection

Secondary BSI Reminders

- · Site-specific infection definitions available for use include:
 - PNEU
 - UTI
 - SSI
 - · CDC/NHSN surveillance definitions for specific types of infections
 - Additionally, a BSI can be attributed to a VAE following the specific VAE protocol guidance for secondary BSI attribution
 - If unable to attribute a BSI as secondary to VAE and a lower respiratory source of infection is thought to be primary source of BSI, the PNEU definitions can be used















a) HAI

- SUTI 1a: CAUTI, DOE 4/20
- The 4/16 asymptomatic urine culture did not meet NHSN UTI criteria, so there was no prior RIT set
- Positive on 4/20 and UTI symptom within the IWP is in the HAI time period





New in 2016

- · Repeat Infection Timeframes (RIT) is not used with SSIs
 - SSIs are procedure based and have long surveillance periods (30 to 90 days)
- SSIs can progress to a deeper level during a surveillance period and a new pathogen can be found.
- Excluded organisms: Organisms belonging to the following genera cannot be used to meet any NHSN definition: Blastomyces, Histoplasma, Coccidioides, Paracoccidioides, Cryptococcus and Pneumocystis.
 - These organisms are typically causes of community-associated infections and are rarely known to cause healthcare-associated infections, and therefore are excluded.

Operative Procedure Updates

- Several operative procedure groups were updated to include the correct ICD-10 or CPT codes
- ICD-10-PCS and CPT code fields remain as optional fields in 2016

PATOS

 The patient does not have to meet the NHSN definition of an SSI at the time of the primary procedure but there must be notation that there is evidence of an infection or abscess present



PATOS FAQ

If an event meets PATOS, do I still have to report as an SSI?

- · Yes, must report but check yes for PATOS
- It only applies if it corresponds to the same depth of SSI that is being attributed to the procedure
- Currently, all PATOS are included in the SIR if wound closure is primary
- PATOS will be evaluated for exclusion from future SSI SIRs calculated using the 2015 baseline

Coming in 2017

- · GI-GIT 2c will be updated
 - GIT-Gastrointestinal tract infection (esophagus, stomach, small and large bowel, and rectum) excluding gastroenteritis, appendicitis, and C. difficile infection
 - The same set of pathogens that are available for use when blood is an element of the criteria for IAB-Intraabdominal (i.e. 2b and 3b) will be the same set of (+) pathogens that are available for GI-GIT 3c.

MRSA/CDI LABID

New in 2016

· Changes to the LabID Event form:

- Has patient been discharged from your facility in the past 4 weeks
 - Changed from three months to better align with CO-HCFA
- · Changed from Optional to Required:
 - Last physical overnight location of patient immediately prior to arrival into facility
 - Has the patient been discharged from another facility in the past 4 weeks?
- CRE Reporting: additional questions added in relation to CRE laboratory test methods

LabID Notes

- LabID events are attributable to the location where the specimen was collected (the 'transfer rule') does NOT apply to LabID event reporting
- Specimens collected from any other affiliated outpatient location (excluding ED and 24-hour observation locations) can be reported for the inpatient admitting location IF collected on the same calendar day as inpatient admission (assigned to admitting inpatient location)



New VAE Information

- New appearance to the VAE calculator
 - Same functionality
 - Addition of 6 antimicrobial agents that were added to the 2016 VAE protocol
 - · Clarification for fever and WBC data entry
- Projected future for VAE:
 - Pediatric VAE available in 2018
 - Pediatric and neonatal locations
 - Single tier algorithm called PedVAC
 - · Adult VAE CDA available in 2019



MDRO/CDI Case Study

- Facility enrolled in NHSN, have FacWideIN and CMS IRF reporting (different CCN)
 - Report MRSA blood and CDI LabID
- August 31, 11am: 55 yo male presents to ED complaining of pain and tenderness of right lower forearm
 - History: discharged from community psychiatric facility on August 15 for tx of depression
 - Pt is known IV drug user and admits to recent use of this area for injection of heroin
 - Temp 100.8F, other vital signs stable
 - Pus from forearm is obtained for culture, area is superficially debrided and a dressing applied
 - · Pt started on trimethoprim-sulfamethoxazole

MDRO/CDI Case Study

- During prep for discharge, the patient complains of chill and vital signs reveal a temp of 101.2F and slight decrease in BP
- September 1, 12:15am: pt placed in 24-hr obs unit where blood is collected for culture and IV fluids started
 - During the evening, patient continues with fever and antibiotic therapy is changed to IV Vancomycin
 - 11pm: patient transferred to 3N stepdown inpatient ward
- September 2: patient remains febrile with a max temp of 102F
 - Periodic drops in BP to 90/60 responsive to fluid boluses
 - Micro notifies physician that blood collected Sept 1 is growing grampositive cocci
 - · Another set of blood cultures are obtained

MDRO/CDI Case Study

- September 2, cont: during rounds, physician detects presence of cardiac murmur and patient is sent for echocardiogram, which is suggestive of right-sided endocarditis
 - · Peripherally-inserted central catheter is placed for vascular access
- September 3: patient remains febrile and ID consultation is obtained
 - Wound and blood cultures from September 1st are growing MRSA
 - Blood cultures obtained on September 2nd are also growing MRSA



c) Yes. The result would be identified as a MRSA bacteremia LabID event for the 24-hour observation unit because this is where the specimen was collected.

RATIONALE: Any specimen, obtained for clinical decision making, testing positive for MRSA that is not a duplicate isolate for the patient and location meets the definition for a MRSA bacteremia LabID event and should be submitted as such. LabID events are attributed to the location where the positive specimen is collected. In this case scenario, the September 1st specimen is collected when the patient is housed on the 24-hour observation unit thus, this is the location of attribution. Note that although emergency departments and 24-hour observation locations are considered outpatient locations by NHSN, as of January 2015, lab ID events attributed to these locations must also be reported as a part of FacWideIN LabID event reporting for facilities participating in the CMS Hospital IQR Program.

• Note: A 'duplicate" isolate is defined as any isolate other than the initial positive isolate for the same patient for the same location.



d) None. The 'admit to facility' question should be left blank

RATIONALE: The question 'date admitted to facility' is optional on all outpatient location based LabID events; regardless of the duration of time between presentation to the outpatient location and the specimen collection date, the 'admit to facility' question may be left blank since all outpatient events are considered community-onset (CO) events.



d) Yes. As there were no prior MRSA positive blood specimens for this patient in this location (3Nstepdown) collected within 14 days, the result would be identified as a unique MRSA bacteremia LabID event for 3N-stepdown.

RATIONALE: LabID event reporting is unique to patient and location. As there were no prior MRSA positive blood specimens for this patient for the 3N-stepdown location, the positive MRSA blood culture is a unique MRSA bacteremia LabID event for 3N-stepdown and should be submitted as a new LabID event. The 14-day rule does not cross locations.



b) September 1st

RATIONALE: For NHSN reporting purposes, the date of admission to the facility is the date the patient physically locates to an inpatient location. As both the ED and the 24hour observation units are outpatient locations for the acute care facility, the date of admission is the date the patient physically locates to the 3N-stepdown inpatient ward, or September 1st. The admit date should only match the date the patient presented to the ED/24-hour observation location if the patient is admitted to an inpatient location on the same calendar day.



a) Community-onset (CO) because the specimen was collected < 3 days after admission to the facility.

RATIONALE: LabID events are categorized using the patient admit date and specimen collection date. A community-onset (CO) event is defined as a positive specimen collected on hospital day 1 (day of admission), hospital day 2 or hospital day 3. Healthcare-onset (HO) events are LabID events where the positive specimen is collected on or after hospital day 4. The Community-onset healthcare facility associated (CO-HCFA) is not available for use with MRSA bacteremia LabID events, as it is specific to C. difficile LabID events only. In this case, September 1st is the date of admission to the facility as it is the date the patient physically located to an inpatient location. The MRSA positive blood culture collected on September 2nd and positive for MRSA was collected on hospital day 2 (date of admission = hospital day 1) and therefore meets the CO definition.

MDRO/CDI Case Study, cont...

- Patient remained on the 3N-stepdown unit for cardiac monitoring and administration of intravenous antibiotics.
- September 17th, the patient is transferred to the CMS IRF unit within your hospital for intensive physical therapy.
 - Patient is noted to have a temperature of 100.4° F and blood is collected for culture on the same day patient arrived in the IRF unit
 - The blood culture is positive for MRSA on the next day

6. Would you identify the blood collected for culture on September 17th and positive for MRSA as a MRSA bacteremia LabID event for your facility?



Answer 6

b) Yes. The result would be identified as a unique MRSA bacteremia LabID event for the inpatient rehabilitation unit because the specimen was collected in a location with no prior MRSA blood culture reported within 14 days for the patient and location.

RATIONALE: The MRSA positive blood collected on September 17th, the day of admission to the IRF, is a unique MRSA bacteremia LabID event for this location and should be reported as a LabID event for the IRF location. For IRFs located within an acute care facility that operate under a unique CCN and participate in the inpatient rehabilitation facility quality reporting (IRFQR) program for CMS, LabID event reporting is a part of required reporting as of 1/1/15. This event is considered a 'unique' MRSA bacteremia LabID event as the 'transfer rule" used in other NHSN modules does not apply to LabID event reporting (as noted in chapter 2 and 12 of the patient safety manual).

7. If the blood collected for culture on September 17th and positive for MRSA is a MRSA bacteremia LabID event for the CMS IRF unit, how will the event be categorized by the NHSN application?





8. If the blood collected for culture on September 17th and positive for MRSA is a MRSA bacteremia LabID event for the CMS IRF unit, what date should be used as "admit to facility date" when reporting?



Answer 8 c) September 1st since that is the date the patient is physically located to an inpatient location in the facility and the stay is considered a 'continuous' hospitalization RATIONALE: For NHSN reporting purposes, the hospitalization is considered "continuous" thus, the "admit to facility date" is the date the patient first locates to an inpatient location for the facility or September 1st.

TAP METHODOLOGY

Targeted Assessment for Prevention (TAP)

• Why TAP?

- · SIRs are not always available or representative
- Hospitals with <1 infections expected won't receive an SIR
- Hospitals with very few expected infections will receive an inflated SIR if they have an infection
- TAP gives hospitals a way to target problem areas and see where they rank within a group









Find TAP Reports in NHSN

Alerts Reporting Plan Reporting Report Repor	
Reporting Plane Patient Event Procedure Symmary Data Description Import/Export Analy Description Description	
Patient : Sevent Procedure Simmary Data Semanta Data Set Sevents Data Set Sevents Data Set Sevents Data Set Sevents Data Set Statistic Calculate Statistic Calculate Statistic Calculate Statistic Calculate Sevents Statistic Calculate Sevents Statistic Calculate Sevents Seve	
Event Patient 1 Procedure Analys Summary Data Import/Export Device-Associated (DA) Module Output Options Device-Associated (DA) Module Distriction Calculator Device-Associated (DA) Module Summary Data Setti Doubut Options Device-Associated (DA) Module Distriction Calculator Device-Associated (DA) Module Surveys DMDRO/CDI Module - LABID Event Reporting Group DMDRO/CDI Module - Process Measures DMDRO/CDI Module - Ductome Measures DMDRO/CDI Module - Colles and Resistance Module CMDRO/CDI Module - Colles and Factor Device Colles double Data Care Hospitals (ACHs) Colles port - CLAB Data for ACHs Data Preport - CALB Data for ACHs Run Modify DTAP Report - CLAB Data for ACHs Run Modify DTAP Report - CLAB Data for ACHs Run Modify	
Procedure Analysis Import/Export Expand All Collapse All Openceate Data Set Device-Associated (DA) Module Openceate Data Set Device-Associated (PA) Module Openceate Data Set Device-Associated (PA) Module Openceate Data Set Device-Associated (PA) Module Device-Associated (PA) Module Device-Associated (PA) Module Device-Associated (PA) Module Device-Associated (PA) Modules Device-Associated (PA) Module Device-Associated (PA) Module Device-Associated (PA) Module Device-Associated (PA) Modules Device-Associated (PA) Module Device-Associated (PA) Modules Device-Associated (PA) Module Device-Associated (PA) Modules Device-Associated (PA) Module - Process Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DANDRO/CDI Module - Outcome Measures DANDRO/CDI Module - Outcome Case Hospitals (ACHs) Device Case Hospitals (ACHs) Decore Defend Outed DTAP Report - CALD Data for ACHs Run Modify DTAP Report - FACVIDEIN COL LabDI Data for ACHs Run Modify DTAP Report - FACVIDEIN COL LabDI Data for ACHs Run Modify	Safe
Summary Data Import/Expose Analysis © Generate Data Sete © Device-Associated (DA) Module © Device-Associated (DA) © Device	ysis C
Import/Export Analysis Deenseta bata 6t Device-Associated (DA) Module Dougue Options Statistics Catolates MDRO/CDI Module - Infection Surveillance MDRO/CDI Module - LABID Event Reporting MDRO/CDI Module - Process Measures MDRO/CDI Module - Otocome Measures MDRO/CDI MODU MDRO/CDI Module - Otocome Measures MDRO/CDI MODU MDRO/CDI MDRO/CDI MODU MDRO/CDI MODU MD	
Ormanizato Data set Dolutivi Optime Statistics Calculate District Scalulate Improcedure-Associated (PA) Module Direct Optime Associated (PA) Module Improcedure-Associated (PA) Module Direct Optime Associated (PA) Module Improcedure-Associated (PA) Modules Direct Optime Associated (PA) Module Improcedure-Associated (PA) Module Direct Optime Associated (PA) Module Improcedure-Associated (PA) Modules Composition Improcedure-Associated (PA) Module Composition Improcedure-Associated (PA) Module Composition Improcedure-Associated (PA) Module Composition Improcedure-Associated (PA) Module Direct Optime Associated (PA) Module - Directome Measures Improcedure-Associated (PA) Improcedure-Associated (PA) Module - Outcome Measures Improcedure-Associated (PA) Improcedure-Associated (PA) Reports Improcedure-Associated (PA) Improcedure-Associated (PA) Report - CAD Data for ACHs Run Modify Improcedure-Associated (PA) Report - CAD Data for ACHs Run Modify Improcedur	
Doubut options Improcedure-Associated (PA) Module Statistic Scaluta Improcedure-Associated (PA) Module Surveys Improcedure-Associated (PA) Modules Surveys Improcedure-Associated (PA) Modules Surveys Improcedure-Associated (PA) Modules Surveys Improcedure-Infection Survelliance Improcedure-Labor Improcedure-Labor Improcedure-Labor Improcedure-Lab	
Bratistics Calculator BHAI Antimicrobial Resistance (DA+PA Modules) Surveys DMDRO/CDI Module - Infection Surveillance Facility DMDRO/CDI Module - LABID Event Reporting Group DMDRO/CDI Module - Process Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Outcome Measures DMDRO/CDI Module - Process Measures DMDRO/CDI Module - Process Measures DMDRO/CDI Module - Process Measures DMDRO/CDI Module - Process Measures DMDRO/CDI Module - Process Measures DMDRO/CDI Module - Process Measures DMDRO/CDI Module - Process Measures<	
Burleys ImMDRO/CDI Module - Infection Surveillance Facility ImMDRO/CDI Module - Infection Surveillance Forup ImMDRO/CDI Module - Process Measures Log Out ImMDRO/CDI Module - Outcome Measures ImMDRO/CDI Module - Outcome Measures ImMDRO/CDI Module - Outcome Measures ImMDRO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Module - Outcome Measures ImmORO/CDI Mod	
Facility IDENSION DATE: ENDING Group IDMDRO/CDI Module - LABID Event Reporting IDMDRO/CDI Module - Process Measures IDMDRO/CDI Module - Outcome Measures IDMDRO/CDI Module - Colloge and Resistance Module IDMDRO/CDI And Resistance Module IDMDRO/CDI And Resistance Module IDMDRO/CDI And Resistance Module IDMORE - Colloge and Resistance Module IDMORE - Collaberator Actis IDMORE - TAP Report - FACWIDEIN CDI LabID data for Actis IDMAR - Report - FACWIDEIN CDI LabID data for Actis	
Group Imposite Content of the product of the produ	
Log Out	
CMS Reports CMS Report - CLAB Data for ACHs CMS Report - CLAB Data for ACHs CMS Report - FACWIDEIN CDL LabID data for ACHs CMS Run Modify CMS Report - FACWIDEIN CDL LabID data for ACHs CMS Run Modify CMS Report - FACWIDEIN CDL LabID data for ACHs CMS Run Modify CMS Report - FACWIDEIN CDL LabID data for ACHs CMS Run Modify CMS Report - FACWIDEIN CDL LabID data for ACHs CMS Run Modify CMS Report - FACWIDEIN CDL LabID data for ACHs CMS Run Modify CMS Report - FACWIDEIN CDL LabID data for ACHs CMS RUN Modify CMS Report - FACWIDEIN CDL LabID data for ACHs CMS RUN Modify CMS RUN MODIFY CMS RUN	
Antimicrobial Ose and Resistance Module CMS Reports CAcute Care Hospitals (ACHs) Control Contended Output TAP Report - CAB Data for ACHs TAP Report - CAU Data for ACHs TAP Report - CAU Data for ACHs TAP Report - FACWIDEIN CDI LabID data for ACHs TAP Report - FACWIDEIN CDI LabID data for ACHs Tau	
CMS Keports CALL Care Hospitals (ACHs) Coc Delined Output Care Hospitals (ACHs) Coc Delined Output Care Hospitals (ACHs) Care Hospi	
AV Reports Avenue Care Hospitals (ACHs) Coco Delevel Output TAP Report - CLAB Data for ACHs TAP Report - CAD Data for ACHs TAP Report - FACWIDEIN CDI LabID data for ACHs TAP Report - FACWIDEIN CDI LabID data for ACHs	
Cutte Care Hospitals (ACHs) Control Content Output TAP Report - CLAB Data for ACHs TAP Report - CAU Data for ACHs TAP Report - CAU Data for ACHs TAP Report - FACWIDEIN CDI LabID data for ACHs TAP Report - FACWIDEIN CDI LabID data for ACHs	
CCC Delived Volput TAP Report - CLAB Data for ACHs TAP Report - CAU Data for ACHs TAP Report - CAU Data for ACHs TAP Report - FACWIDEIN CDL LabID data for ACHs TAP Report - FACWIDEIN CDL LabID data for ACHs	
TAP Report - CLAB Data for ACHs Run Modify TAP Report - CAU Data for ACHs Run Modify TAP Report - FACWIDEIN CDI LabID data for ACHs Run Modify	
TAP Report - CAU Data for ACHs Run Moddy TAP Report - FACWIDEIN CDI LabID data for ACHs Run Modfy	
TAP Report - FACWIDEIN CDI LabID data for ACHs Run Modify	
A DECEMBER OF A	
Inpatient Rehabilitation Facilities (IRFs)	
Long Term Acute Care Hospitals (LTACHs)	
□Advanced	
□My Custom Output	
Published Output	

Make	Modificat	ions in NH	SN	
	Modify Attributes of the Output:			
	Last Modified On: 03/23/2016			
	Output Type: TAP			
	Output Name: TAP Report - CLAB Data for ACHs	()		
	Output Title: TAP Report - CLABSI Data for Act	Ite Care Hospitals		
	Select output format:	ng		
	Output Format: HTML			
	Select a time period or Leave Blank for Cum Date Variable Beginning Ending summaryYQ v 2015Q3 2015Q3 Enter Date variable/Time period at the time	ulative Time Period: Units Clear Time Period a you click the Run button		
	Specify Other Selection Criteria: OHER Show Criteria Column + Row + Clear Criter	ia		
	×	~ ~	Y	
	Other Options:	Print Variable Reference List		
	Cumulative Attributable Difference (CAD) M	uttinling		

NHSN TAP Output

National Healthcare Safety Network TAP Report - CLABSI Data for Acute Care Hospitals Locations Ranked by CAD Within a Facility

Cumulative Attributable Difference (CAD) Multiplier: HHS Goal = 0.5 As of: April 26, 2016 at 9:52 AM

	FACILITY						LOCATION					
orgID	name	facCAD	locRank	location	loccdc	infCount	numcidays	locDUR	locCAD	loc SIR	SIRtest	numPathBSI
15165	NHSN State Users Test Facility #2	2.28	1	5M	IN:ACUTE:WARD:M	1	50	14	0.96			3 (1, 0, 1, 0, 0, 1
			2	5ICU	IN:ACUTE:CC:N	1	140	37	0.90			2 (0, 0, 1, 0, 0, 0
			3	1	IN:ACUTE:CC:MS	1	200	40	0.79			2 (0, 0, 1, 1, 0, 0
			4	L600	IN:ACUTE:WARD:M	0	25	17	-0.02			
			4	L700	IN:ACUTE:WARD:MS	0	30	60	-0.02			
			6	L200	IN:ACUTE:CC:MS	0	50	50	-0.05			
			7	L800	IN:ACUTE:WARD:S	0	100	57	-0.07			
			8	L300	IN:ACUTE:CC:S	0	75	33	-0.09			
		İ	9	L100	IN:ACUTE:CC:M	0	100	50	-0.13			

If location-level CADs are the same in a given faolity, their ranks are ted. (CMS, VS, SA, ESK, SE, O) = No. of CMS, Yeast (both candids and non-candids species). Staph sureus, Entercooccus species, K pneumoniae/K, oxytoca, E. coli SIR set to: "Imake superside number of events is r.1.0. LOCATION CAD = (D685ER/EQD_LOCATION - EXPECTED_LOCATION*SELECTED CAD MULTIPLIER) SIR TEST = "SIG means SIR", SIR Good significantly Data contained in this report were last generated on April 25, 2016 at 11:40 AM.



TAP Answer 1

b) No

RATIONALE: SIRs with fewer than one infection predicted will produce a very high SIR if the facility has an infection; this is not necessarily representative of their infection prevention efforts



TAP Answer 2

a) Yes

RATIONALE: The CAD is a concrete number of infections; while this may be very small, it allows hospitals with few predicted infections to get an accurate idea of the number of infections needed to prevent to reach a target



TAP Answer 3

a) True

RATIONALE: any number >0 indicates the number of infections needed to prevent in order to reach the target SIR (may or may not be whole number)

TAP IN MICHIGAN





Michigan 2015 CAD Trends





REBASELINE

2015 Baseline

- Data reported to NHSN for 2015 complete year
- All applicable factors have been assessed/re-assessed
 Including quarterly prevalence rates and quarterly CDI test type for LabID
- December 10th: scheduled release data for NHSN v8.6
- This baseline will not be updated each year once it is established

Rebaseline Webinar

- New Standardized Utilization Ratio (SUR)
 - · Ratio of observed device days / predicted device days
 - · Will be available for catheter, central line, and ventilator usage
 - Not part of CMS reporting
- To create the new baseline data:
 - · Potential risk factors were established by subject matter experts
 - · Risk factors were then analyzed using different regression analyses
 - · SSI procedures were each modeled separately

Rebaseline Webinar

- Future output options
 - · No more pooled means or device utilization ratios
 - Moving to all SIRs and SURs

Data limitations

- · Device data can only be narrowed down to location-level
 - · Can't get patient-specific data
- · LabID data can be narrowed down to inpatient facility-wide
 - · Can't get patient- or location-specific data

Rebaseline Webinar – CMS Data

- 2016 Q1 and Q2 data have been shared using the 2015 baseline
- 2015 frozen data were re-submitted compared to new baseline (so old and new SIRs are on record)
 - Datasets were not regenerated previous raw data were used
- CMS preview reports for 2015 Q1-Q4 are available in quality net secure portal beginning October 8

NHSN V8.6 RELEASE





Location-Level Summary Data Reporting

- Patient days reported on location-specific DA summary records will need to match those reported on locationspecific MDRO summary records
- Will get a pop-up if the same number of patient days for a specific location are not reported on both summary record types for the month

COMING IN 2017

NHSN Annual Training

- March 20th-24th
- · Registration to open in December

NHSN Organism List Update

January 2017 updates:

- All organisms
 - · Addition of organisms from a university lab information system
 - · Taxonomic updates according to SNOMED CT; inactivate old organisms

Common commensals

- · Add organism to the list if moved to new genus: entire genus
- MBI-LCBI Organisms
 - · Addition of missing Enterobecteriaciae and viridans group streptococci
 - · Add organism to the list if moved to new genus: entire genus
- UTI Bacteria
 - · Expands from newly added bacteria

2017 Patient Safety Component Manual

- Manual will be released November 2016
 - · Document summarizing the updates will be emailed
- · Changes will come into effect January 1, 2017
- Updates include (similar in scale to 2016):
 - Clarifications
 - · Modifications in response to questions/suggestions

Thank you!

Allie Murad, MPH Michigan Department of Health and Human Services SHARP Unit <u>murada@michigan.gov</u> <u>www.michigan.gov/hai</u>

Join us for Michigan NHSN User Group Calls every other month! Next Call: Wednesday, November 16th at 10am